Global Leukocyte Surface Antigen CD47 Market Strategic Research Report

Scope of the Report

The global Leukocyte Surface Antigen CD47 market size is predicted to grow from US$ 32.28 million in 2025 to US$ 64.38 million in 2032; it is expected to grow at a CAGR of 10.4% from 2026 to 2032.

Leukocyte Surface Antigen CD47 refers to a biologically and commercially defined target centered on the CD47 antigen. In the market, the sellable products are usually not the native antigen in the human body itself, but antibodies, recombinant proteins, assay kits, binding reagents, and preclinical or clinical blocking molecules developed around this target. The native molecule is a broadly expressed glycosylated transmembrane protein on the cell surface; commercial forms are commonly clear to slightly opalescent liquids, lyophilized powders, or pre-coated microplate kits. Structurally, it contains an extracellular immunoglobulin-like domain, multiple transmembrane regions, and a short intracellular tail. Its product composition may include mammalian-cell-expressed recombinant protein, hybridoma-derived or recombinantly expressed monoclonal antibodies, fluorescent or enzyme-conjugated antibodies, and engineered fusion proteins. Leukocyte Surface Antigen CD47 products belong to life-science research reagents, immunoassay raw materials, and oncology immunotherapy target-development materials. Key technical requirements include high purity, lot-to-lot consistency, correct conformation, low endotoxin, defined species reactivity, and validated binding activity. Its functional principle is to detect or modulate the interaction between this antigen and phagocyte receptors, supporting cell phenotyping, tissue staining, antibody screening, binding-kinetics testing, tumor-immunology research, and candidate-drug evaluation.

Market opportunities are mainly driven by the extension of oncology immunology from adaptive immune checkpoints to innate immune checkpoints. Leukocyte Surface Antigen CD47 is linked to phagocytosis-suppressive signaling, so it supports basic research, flow-cytometry detection, tissue staining, antibody screening, and candidate-drug evaluation. As combination therapy, biomarker stratification, and low red-blood-cell binding designs become the focus of development, research antibodies, recombinant proteins, binding-assay materials, and preclinical functional antibodies still have room for steady growth. For suppliers, the key opportunity is not ordinary catalog antibodies alone, but high-consistency, low-endotoxin, clone-defined, cross-species-validated, and functionally blocking product portfolios.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Leukocyte Surface Antigen CD47 market?

What factors are driving Leukocyte Surface Antigen CD47 market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Leukocyte Surface Antigen CD47 market opportunities vary by end market size?

How does Leukocyte Surface Antigen CD47 break out by Type, by Application?

This report presents a comprehensive overview of the global Leukocyte Surface Antigen CD47 market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• B-6H12
• ALX-148
• CC-90002
• PSTx-23
• Others

Segment by Commercial Product Form

• Anti-CD47 Antibodies
• Recombinant CD47 Proteins
• CD47 Assay Kits
• Others

Segment by Molecular Modality

• Antibodies
• Fusion Proteins
• Small Molecules and Peptides
• Others

Segment by Manufacturing System

• Mammalian Cell Expression Products
• Hybridoma-derived Products
• Microbial Expression Products
• Others

Segment by Application

• Lymphoma
• Ovarian Cancer
• Ischemia Reperfusion Injury
• Kindney Transplant Rejection
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Leukocyte Surface Antigen CD47 market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Lymphoma, Ovarian Cancer, Ischemia Reperfusion Injury evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact